Brokers Offer Predictions for Immunovant FY2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Immunovant in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of ($2.92) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.75) per share.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same quarter in the prior year, the business posted ($0.45) EPS.

IMVT has been the subject of several other research reports. Wells Fargo & Company decreased their price objective on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Wolfe Research downgraded shares of Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $51.00 target price on shares of Immunovant in a research note on Friday, November 8th. Bank of America decreased their target price on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, January 15th. Finally, Raymond James reiterated an “outperform” rating and set a $36.00 target price on shares of Immunovant in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Immunovant Price Performance

NASDAQ IMVT opened at $23.05 on Thursday. Immunovant has a 1 year low of $22.41 and a 1 year high of $39.55. The company has a market capitalization of $3.38 billion, a PE ratio of -10.38 and a beta of 0.66. The company has a fifty day moving average of $25.93 and a two-hundred day moving average of $28.39.

Insider Buying and Selling

In related news, CTO Jay S. Stout sold 2,195 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $23.59, for a total transaction of $51,780.05. Following the completion of the transaction, the chief technology officer now directly owns 139,991 shares of the company’s stock, valued at $3,302,387.69. This represents a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mark S. Levine sold 3,650 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $25.45, for a total transaction of $92,892.50. Following the transaction, the insider now directly owns 319,228 shares of the company’s stock, valued at $8,124,352.60. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,892 shares of company stock valued at $1,811,857 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV increased its holdings in Immunovant by 46.2% in the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock valued at $55,000 after buying an additional 612 shares in the last quarter. Assetmark Inc. increased its holdings in Immunovant by 73.8% in the third quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock valued at $82,000 after buying an additional 1,228 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Immunovant by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after buying an additional 934 shares in the last quarter. Bank Pictet & Cie Europe AG purchased a new position in Immunovant in the third quarter valued at about $261,000. Finally, Scientech Research LLC purchased a new position in Immunovant in the second quarter valued at about $334,000. 47.08% of the stock is owned by hedge funds and other institutional investors.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.